Eli Lilly is making a massive investment to address surging demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro. The company announced an additional $5.3 billion for its new manufacturing plant in Lebanon, Indiana, bringing the total investment to a staggering $9 billion.
This significant expansion is aimed at boosting production of the drugs’ active ingredients. Both Zepbound and Mounjaro have been experiencing shortages in the US, and Lilly expects limited availability to continue through the second quarter of 2024.
The company acknowledges the challenges and expects supply of Zepbound to remain tight for some time. However, this investment positions them to increase production capacity and meet the growing demand for these medications. This move also solidifies Lilly’s commitment to US-based manufacturing, with a total of $16 billion invested in new facilities since 2020.
Source: Reuters